XML 26 R13.htm IDEA: XBRL DOCUMENT
v3.21.1

Other Accrued Liabilities | 3 Months Ended
--- | ---
Mar. 31, 2021
Other Accrued Liabilities [Abstract] |
Other Accrued Liabilities | Note 7 Other Accrued Liabilities: Other accrued liabilities consist of:
|  | March 31, 2021 |  |  | December 31, 2020 |
Accrued warranty, current |  | $ | 63 |  |  | $ | 87 |
Accrued compensation, including commissions and vacation |  |  | 1,491 |  |  |  | 891 |
Accrued state sales, use and other taxes |  |  | 3,150 |  |  |  | 3,105 |
Accrued professional fees and other accrued liabilities |  |  | 582 |  |  |  | 607 |
Total other accrued liabilities |  | $ | 5,286 |  |  | $ | 4,690 |
Accrued State Sales and Use Tax In the ordinary course of business, the Company is, from time to time, subject to audits performed by state taxing authorities. These actions and proceedings are generally based on the position that the arrangements entered into by the Company are subject to sales and use tax rather than exempt from tax under applicable law. The Company uses estimates when accruing its sales and use tax liability. All of the Company’s tax positions are subject to audit. One state has assessed the Company, in two assessments, an aggregate amount of $1,484 for the period from March 2014 through February 2020, including penalties and interest. The Company has declined an informal offer to settle at a substantially lower amount, and the Company appealed in that jurisdiction’s administrative process of appeal. In January 2021, the Company received notification that the administrative judge from the respective state had issued an opinion finding in favor of the Company that the sale of XTRAC treatment codes were not taxable as sales tax with respect to the first assessment. The jurisdiction has filed an appeal of the administrative law judge’s finding, but has not yet submitted a legal brief to support the appeal. A second jurisdiction has made an assessment of $720 from June 2015 through March 2018 plus interest of $171 through April 2020. The Company is also in that jurisdiction’s administrative process of appeal and the timing of the process has been impacted by the COVID-19 pandemic. If there is a determination that the true object of the Company’s recurring revenue model is not exempt from sales taxes and is not a prescription medicine or the Company does not have other defenses where the Company does not prevail, the Company may be subject to sales taxes in those particular states for previous years and in the future, plus potential interest and penalties for failure to pay such taxes. The Company believes its state sales and use tax accruals have properly recognized such that if the Company’s arrangements with customers are deemed more likely than not that the Company would not be exempt from sales tax in a particular state are the basis for measurement of the state sales and use tax is calculated in accordance with ASC 405, Liabilities as a transaction tax. If and when the Company is successful in defending itself or in settling the sales tax obligation for a lesser amount, the reversal of this liability is to be recorded in the period the settlement is reached. However, the precise scope, timing and time period at issue, as well as the final outcome of any audit and actual settlement remains uncertain. The Company records state sales tax collected and remitted for its customers on equipment sales on a net basis, excluded from revenue. The Company’s sales tax expense that is not presently being collected and remitted for the recurring revenue business is recorded in general and administrative expenses on the condensed consolidated statements of operations. Accrued Warranty Costs The Company offers a standard warranty on product sales generally for a one to two-year period, however, the Company has offered longer warranty periods, ranging from three to four years, in order to meet competition or meet customer demands. The Company provides for the estimated cost of the future warranty claims on the date the product is sold. Total accrued warranty is included in other accrued liabilities and other liabilities on the condensed consolidated balance sheet. The activity in the warranty accrual during the three months ended March 31, 2021 and, 2020, is summarized as follows:
|  | Three Months Ended, March 31, |
|  | 2021 |  |  | 2020 |
Accrual at beginning of period |  | $ | 113 |  |  | $ | 232 |
Additions charged to warranty expense |  |  | 4 |  |  |  | 3 |
Expiring warranties/claimed satisfied |  |  | (32 | ) |  |  | (54 | )
Total |  |  | 85 |  |  |  | 181 |
Less: current portion |  |  | (63 | ) |  |  | (143 | )
Total long-term accrued warranty costs |  | $ | 22 |  |  | $ | 38 |

X
- Definition The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period. + References No definition available. + Details
Name: | us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OtherLiabilitiesDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration